Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Connor Frey

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|April 26, 2025
A Real-World Pharmacovigilance Analysis of Lorlatinib-Associated Metabolic Effects Using the FDA Adverse Events Reporting System (FAERS) Database From 2013 to 2024Connor Frey
Urologia|April 30, 2026
Association between immune-mediated cystitis and PD-1, PD-L1, CTLA-4, and LAG-3 immune checkpoint inhibitors: A pharmacovigilance study from the FAERS databaseConnor Frey
Transplantation and Cellular Therapy|June 11, 2026
T-Cell Lymphoma Associated with CAR-T Cell Therapy: A Bayesian Disproportionality Analysis of a National DatabaseConnor Frey
Japanese Journal of Clinical Oncology|July 1, 2026
Immune effector cell-associated hematotoxicity following CAR-T cell therapies: insights from a large national databaseConnor Frey
Plos One|August 19, 2025
A real-world pharmacovigilance analysis of ALK inhibitor-associated pleural and pericardial effusion using the FDA Adverse Events Reporting System (FAERS) database from 2013 to 2024Connor Frey
Investigational New Drugs|June 19, 2026
Characterizing the post-market safety profile of cemiplimab: a pharmacovigilance study of the FDA adverse events reporting system databaseConnor Frey
Canadian Journal of Physiology and Pharmacology|April 30, 2025
Disproportionality Analysis of ALK Inhibitor-Induced Hemolytic Adverse Events: A Pharmacovigilance Study Using the FDA Adverse Event Reporting System DatabaseConnor Frey
Schizophrenia Research|September 10, 2025
Disproportionality signal for myopia associated with aripiprazole: Analysis of the FAERS database and review of the literatureConnor Frey
Journal of Chemotherapy (Florence, Italy)|September 18, 2025
Characterizing pulmonary adverse events associated with the immune checkpoint inhibitor avelumab: a FAERS-based pharmacovigilance study from 2013 to 2024Connor Frey
Pharmacoepidemiology and Drug Safety|January 22, 2025
Hepatobiliary Adverse Events Associated With the KRAS p.G12C Inhibitor SotorasibConnor Frey
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|April 26, 2025
A Real-World Pharmacovigilance Analysis of Lorlatinib-Associated Metabolic Effects Using the FDA Adverse Events Reporting System (FAERS) Database From 2013 to 2024Connor Frey
Urologia|April 30, 2026
Association between immune-mediated cystitis and PD-1, PD-L1, CTLA-4, and LAG-3 immune checkpoint inhibitors: A pharmacovigilance study from the FAERS databaseConnor Frey
Transplantation and Cellular Therapy|June 11, 2026
T-Cell Lymphoma Associated with CAR-T Cell Therapy: A Bayesian Disproportionality Analysis of a National DatabaseConnor Frey
Japanese Journal of Clinical Oncology|July 1, 2026
Immune effector cell-associated hematotoxicity following CAR-T cell therapies: insights from a large national databaseConnor Frey
Plos One|August 19, 2025
A real-world pharmacovigilance analysis of ALK inhibitor-associated pleural and pericardial effusion using the FDA Adverse Events Reporting System (FAERS) database from 2013 to 2024Connor Frey
Investigational New Drugs|June 19, 2026
Characterizing the post-market safety profile of cemiplimab: a pharmacovigilance study of the FDA adverse events reporting system databaseConnor Frey
Canadian Journal of Physiology and Pharmacology|April 30, 2025
Disproportionality Analysis of ALK Inhibitor-Induced Hemolytic Adverse Events: A Pharmacovigilance Study Using the FDA Adverse Event Reporting System DatabaseConnor Frey
Schizophrenia Research|September 10, 2025
Disproportionality signal for myopia associated with aripiprazole: Analysis of the FAERS database and review of the literatureConnor Frey
Journal of Chemotherapy (Florence, Italy)|September 18, 2025
Characterizing pulmonary adverse events associated with the immune checkpoint inhibitor avelumab: a FAERS-based pharmacovigilance study from 2013 to 2024Connor Frey
Pharmacoepidemiology and Drug Safety|January 22, 2025
Hepatobiliary Adverse Events Associated With the KRAS p.G12C Inhibitor SotorasibConnor Frey
Pageof 4